30 Sep 2019 Cellular Logistics to collaborate in major NIH-funded project to characterize new biomatrix for treating heart failure
Madison, WI., October 1, 2019 – UW-Madison physician researchers Amish Raval, M.D., and Tim Kamp, M.D., Ph.D., have been awarded a U01 Research Project Cooperative Agreement by The National Institutes of Health. Cellular Logistics, a UW spinout co-founded by Dr. Raval that is creating a new way to treat heart damage, and FujiFilm Cellular Dynamics Inc., a world leader in stem-cell technologies, are industry partners in the grant. The $765,000 grant will be matched by the collaborators with cash and in-kind contributions of research material, cells, and services. “This grant funding will enable the first major pre-clinical study of the combination of our Tandem HF technology and a well-characterized cardiovascular cell therapy,” said Alex Vodenlich, president and CEO of Cellular Logistics. “We anticipate that the study will demonstrate not only the safety and efficacy of this combination, but also the therapeutic improvements Tandem HF provides with its enhanced delivery and retention capabilities. We believe the study and its results will serve as a strong foundation for additional studies that will further refine and advance our technology and its ability to change the lives of health failure patients. “This grant award by the NIH is a significant step forward for Cellular Logistics’ work to improve the health and quality of life of heart disease patients by creating a way to treat them where none exists today,” said Dr. Raval, the grant recipient, and co-founder and chairman of Cellular Logistics. “Our pioneering Tandem HF biomatrix promises to change the treatment of heart failure by delivering the right therapy to the right location in the heart muscle and ensuring that it stays there. Cellular Logistics holds an exclusive license from the Wisconsin Alumni Research Foundation to the Tandem technology, which was discovered in Dr. Raval’s lab.
About Cellular Logistics
Cellular Logistics is focused on improving patient outcomes and the quality of life of heart disease patients. Our pioneering platform technology, Tandem™, promises to radically change patient treatment in the aftermath of a heart attack by delivering therapies to the right location in the heart and providing a novel cellular scaffolding that ensures retention and promotes healing. Founded by visionary, trusted clinicians and scientists, we are not only developing new ways to deliver heart treatments, we are creating an entirely new market for companion therapy products. Our dedication to improving the lives of patients coupled with our commitment to remaining innovative and collaborative enables us to deliver a truly differentiated therapeutic product for the treatment of cardiac disease.